Threat posed by unproven drugs in medical oncology

Por Pondé, Noam, Ades, Felipe, de Azambuja, Evandro
Publicado no ESMO Open (2016)

Cancer and the arts: why we need works by long-term survivors

Por Wagner, Wolfgang
Publicado no ESMO Open (2016)

Radiological staging in pregnant patients with cancer

Por Woitek, Ramona, Prayer, Daniela, Hojreh, Azadeh, Helbich, Thomas
Publicado no ESMO Open (2016)

Cancer and the arts: La Madonna dei Tumori, Ravenna, Italy

Por Wagner, Wolfgang
Publicado no ESMO Open (2016)

Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries

Por Sternberg, Cora N
Publicado no ESMO Open (2016)

Immune-related response criteria: light and shadows

Por Merlano, Marco, Occelli, Marcella, Garrone, Ornella
Publicado no ESMO Open (2016)

I-SPY 2: optimising cancer drug development in the 21st century

Por Bartsch, Rupert, de Azambuja, Evandro
Publicado no ESMO Open (2016)

Where do they come from? A call for complete transparency regarding the origin of human tissues in research

Por Hildebrandt, Sabine, Seidelman, William E
Publicado no ESMO Open (2017)

TAS-102 and the quest for predictive biomarkers

Por van der Velden, Daphne L, Opdam, Frans L, Opdam, Frans L
Publicado no ESMO Open (2017)

Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape

Por Oosting, Sjoukje F, Fehrmann, Rudolf S, de Vries, Elisabeth G E
Publicado no ESMO Open (2017)

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid

Por De Mattos-Arruda, Leticia
Publicado no ESMO Open (2017)

Admission of critically ill patients with cancer to the ICU: many uncertainties remain

Por Koutsoukou, Antonia
Publicado no ESMO Open (2017)

Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’

Por Bakalos, Georgios, Schreitmüller, Thomas
Publicado no ESMO Open (2017)

The integrating nutritional therapy in oncology (INTO) project: rationale, structure and preliminary results

Por Caccialanza, Riccardo, De Lorenzo, Francesco, Pedrazzoli, Paolo
Publicado no ESMO Open (2017)

Cancer and the arts: how often do doctors only see what they want to see? Or: the case of an ‘epidemic of breast cancer among famous artists’

Por Wagner, Wolfgang
Publicado no ESMO Open (2017)

Correction: Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice

Publicado no ESMO Open (2018)

Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’

Por Karlin-Neumann, George
Publicado no ESMO Open (2018)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?

Por Poggio, Francesca, Lambertini, Matteo, de Azambuja, Evandro
Publicado no ESMO Open (2018)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

Por Lambertini, Matteo, Viglietti, Giulia, de Azambuja, Evandro
Publicado no ESMO Open (2018)

Controversies in oncology: surgery for small cell lung cancer? It’s time to rethink the case

Por Hoda, Mir Alireza, Klikovits, Thomas, Klepetko, Walter
Publicado no ESMO Open (2018)